bd2-selective bet inhibitor nuv-868

Generic: BD2-selective BET Inhibitor NUV-868

bd2-selective bet inhibitor nuv-868: developed by 1 company · 1 clinical trial tracked.

What we can confirm

1 tracked trial

What it means

Source-backed records connect bd2-selective bet inhibitor nuv-868 to NUVB; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

How could bd2-selective bet inhibitor nuv-868 → NUVB affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Related indications

Advanced Solid TumorBreast Cancer Breast Carcinoma Cancer of the Pancreas Cancer of the Prostate Ovarian Cancer Ovary Cancer Pancreas Cancer

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)

Company	Phase	Indication
Nuvation Bio Inc. (NUVB) Advanced Solid Tumor	Phase 1	Advanced Solid Tumor

Clinical Trials (1)

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT05252390·Phase 1·NUVB

Terminated

Primary endpoint: Phase 1 Monotherapy Dose Escalation: Safety and tolerability of NUV-868 to determine the recommended Phase 2 dose (RP2D)

Interventionalopen82 targetStarted 2022-03Completion 2024-0722 sites · Australia, United StatesNuvation Bio Inc.

Frequently asked questions

Who is developing bd2-selective bet inhibitor nuv-868?

bd2-selective bet inhibitor nuv-868 is being developed by Nuvation Bio Inc..

How many clinical trials involve bd2-selective bet inhibitor nuv-868?

BioSniper tracks 1 clinical trial involving bd2-selective bet inhibitor nuv-868.